Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Non-Current Deffered Revenue (2023 - 2024)

Historic Non-Current Deffered Revenue for Immunome (IMNM) over the last 2 years, with Q1 2024 value amounting to $2.2 million.

  • Immunome's Non-Current Deffered Revenue fell 7656.3% to $2.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $2.2 million, marking a year-over-year decrease of 7656.3%. This contributed to the annual value of $5.5 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q1 2024, Immunome's Non-Current Deffered Revenue is $2.2 million, which was down 7656.3% from $5.5 million recorded in Q4 2023.
  • Over the past 5 years, Immunome's Non-Current Deffered Revenue peaked at $9.4 million during Q1 2023, and registered a low of $2.2 million during Q1 2024.